NCT06571162 A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients
| NCT ID | NCT06571162 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Intermountain Health Care, Inc. |
| Condition | Atherosclerotic Cardiovascular Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-01-30 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2025-01-30 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients who had an ASCVD event at an Intermountain hospital will be screened for eligibility to be randomized. Subjects who meet eligibility criteria will be randomized 1:1 to receive targeted care of their LDL-C through a pharmacist-driven management program or not. Patients may opt-out of receiving LDL-C management by the pharmacy team at any time. The purpose of this program is to increase the proportion of patients who achieve guideline-based recommendations of LDL-C levels of \<70 mg/dL by increasing statin and/or LLT adherence and LDL-C testing. Data collection as part of the study will continue until the last person randomized has had 1-year of follow-up.
Eligibility Criteria
Inclusion Criteria: 1. Male or female \>18 years of age 2. Receive follow-up care with Intermountain Health 3. Value-based patient (as defined in the EDW) 4. Documentation of an ASCVD diagnosis, by 1 of the following: * Coronary artery disease (Primary inpatient CAD diagnosis during index encounter; Primary inpatient MI diagnosis during index encounter; PCI during index encounter; or CABG during index encounter * Cerebrovascular accident (Primary inpatient ischemic stroke diagnosis during index encounter; Carotid endarterectomy during index encounter; or Carotid stent during index encounter) * Peripheral arterial disease (Bypass or percutaneous intervention during index encounter) Exclusion Criteria: 1. Patient age \<18 years. 2. Receipt of or expected receipt of palliative care, expected discharge to hospice, or long-term care facility (i.e., skilled nursing facility). 3. Pregnant or lactating women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06571162 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atherosclerotic Cardiovascular Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06571162 currently recruiting?
Yes, NCT06571162 is actively recruiting participants. Contact the research team at kirk.knowlton@imail.org for enrollment information.
Where is the NCT06571162 trial being conducted?
This trial is being conducted at Salt Lake City, United States.
Who is sponsoring the NCT06571162 clinical trial?
NCT06571162 is sponsored by Intermountain Health Care, Inc.. The trial plans to enroll 400 participants.